TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02403778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VESANOID
Description: All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). VESANOID is a standard treatment for patients with acute promyelocytic leukemia (APL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Ipilimumab is current standard of care treatment for melanoma.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab is current standard of care treatment for melanoma.
Study: NCT00559351

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transthoracic esophagectomy 2-field extended lymphadenectomy
Description: right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)
Description: 21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: neoadjuvant chemoradiotherapy
Description: 21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
Study: NCT04063904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: One 200 mg pill (oral)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Two 400 mcg pills (sublingual)
Study: NCT04455295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transdermal Vagus Nerve Stimulation (tVNS)
Description: Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Vagus Nerve Stimulation (tVNS)
Description: Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Vagus Nerve Stimulation (tVNS)
Description: Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transdermal Vagus Nerve Stimulation (tVNS)
Description: Mild non-invasive transdermal electrical stimulation at the ear (0.0-1.0 mA, 0.0-30.0 Hz). Used in previous studies with no unexpected adverse events. Stimulator not considered a FDA regulated device in previous studies.
Study: NCT05847335

Intervention type: BEHAVIORAL
Intervention: Survey work
Description: Childhood Trauma scale, Personality Beliefs questionnaire, Emotional Intelligence scale
Study: NCT03919266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention: Combined use of a respiratory broad panel multiplex PCR and procalcitonin
Description: The actions or procedures added by the research are the realization of a nasopharyngeal swab in the two strategies, and the PCT assay at D1, D3 and D7 in the pathogen-directed strategy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control: usual antibiotic treatment
Description: usual antibiotic treatment
Study: NCT02903381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral, predetermined dosage, Days 1-21 of cycle 1-12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral, Days 1, 8, 15 of cycle 1-6
Study: NCT02820103

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text+Visual BCT-based intervention
Description: Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-only BCT intervention
Description: Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leaflet information (control)
Description: Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet information (control)
Description: Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Leaflet information (control)
Description: Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
Study: NCT03109925

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DC Lumi Bead, BTG
Description: Embolic agent which is radio-opaque
Study: NCT00573820

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
Study: NCT02261142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multifocal TENS garment (Mollii®)
Description: Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Multifocal TENS garment (Mollii®)
Description: Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
Study: NCT01062295

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Siesta-System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard headrest
Study: NCT04595812

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 200mcg Tab vaginal
Description: 2 tablets vaginally 1 hour before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: 30 IU oxytocin in 500 ml normal saline at a rate of 120 ml/h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbetocin
Description: 100 μg IV Carbetocin (1ml) in 5 ml saline over 1 minute

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pericervical hemostatic tourniquet
Description: a Foley catheter size 18, which will be firmly tied at the level of the cervico-isthmic junction of the uterus before the uterine incision,The time of tourniquet administration will be recorded, and will be released not later than 45 minutes after its application. For those requiring multiple applications, the tourniquet will be reapplied after a period of at least 15 minutes.
Study: NCT03927755

Intervention type: OTHER
Intervention: Education
Description: Physicians will undergo training on how to rapidly obtain appropriate images.

Intervention type: OTHER
Intervention: Education
Description: Physicians will undergo training on how to rapidly obtain appropriate images.
Study: NCT01529216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIAMOND System
Description: Electrical stimulation to the fundus

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DIAMOND System
Description: Electrical stimulation to the fundus
Study: NCT02256774

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combivir®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Study: NCT00775307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAZOPANIB
Description: 400 mg/day (24 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 400 mg/day (24 weeks)
Study: NCT00676039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Venlafaxine
Description: NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
Study: NCT02137681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
Study: NCT01663805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Everolimus
Description: Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
Study: NCT00667589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: urea 40% cream
Description: urea 40% cream applied twice per day to affected areas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluocinonide 0.05% cream
Description: fluocinonide 0.05% cream applied twice per day to affected areas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tazarotene 0.1% cream
Description: tazarotene 0.1% cream applied twice per day to affected areas

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bland emollient cream (Udderly smooth® Udder Cream)
Description: bland emollient cream applied twice per day to affected areas
Study: NCT00711204

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil Hydrochloride (Aricept)
Description: 5mg (or 10mg) tablet, once daily, with a full glass of water.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride (Aricept)
Description: 5mg (or 10mg) tablet, once daily, with a full glass of water.
Study: NCT01893762

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Description: Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anaerobic exercise
Description: Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
Study: NCT03907956

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry Needling with Fascial Winding Technique
Description: For placement of Dry Needling (DN) needles with Fascial Winding Technique (FWT) according to the Four-pole Carpal Dry Needling (FCDN) approach model, only anatomical references are used, in all cases from a carpal ventral approach. The needles used are the Chinese type with silver handle and guide tube, measuring 25x0.30 mm., Agupunt® brand. Four needles are placed, at the level of the bones: scaphoid, pisiform, trapezius and hamate. The four needles follow an oblique direction, always on the back and looking for the midline of the center of the carpal tunnel, with an inclination of approximately 45º, both in the cranio-caudal and medial-lateral directions. In each of the needles, it deepens until it reaches a firm elastic stop, attributable to the Transverse Carpal Ligament. Next, the FWT is applied to each of the needles, consisting of rotating them in the same direction until you feel the final stop of the needle grasp.
Study: NCT01433770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amevive
Description: Alefacept 15mg subcutaneous; once a week for 12 weeks
Study: NCT04604093

Intervention type: DEVICE
Intervention: SMBG Meter
Description: Self Monitoring Blood Glucose Meter

Intervention type: DEVICE
Intervention: FreeStyle Libre 2 System
Description: The Abbott's FreeStyle Libre 2 Flash Glucose Monitoring System
Study: NCT03280030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: Midostaurin 50 mg \[two 25 mg capsules\] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
Study: NCT02194686

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: One tablet (100 mg) twice per day for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dummy Placebo
Description: One tablet twice per day for 12 weeks
Study: NCT04095936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Subcutaneous administration of 0 to 20ug/kg for 6 months
Study: NCT01572688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: powder for injection, 200mg/m2, uses after reconstituted within 24 hours
Study: NCT03220555

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Buzzy® device
Description: Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EMLAPATCH (lidocaine, prilocaine)
Description: The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
Study: NCT00537082

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Administered orally once daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720
Description: Administered orally once daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally once daily for 6 months
Study: NCT00655746

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Omeprazole
Description: Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
Study: NCT04241718

Intervention type: DEVICE
Group type: OTHER
Intervention: Aquadex FlexFlow System and BVA-100
Description: Aquapheresis therapy with Aquadex FlexFlow System and Blood Volume Measurement with BVA-100
Study: NCT03819205

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kinesiotaping
Description: The participants will receive kinesiotaping treatment on the affected side for the hemiplegic CP's and for diplegic, tetraplegic CP's the side of upper extremity which children have been used to but have obstacles in daily life for 1 week at least 2-3 hours a day, renewing if it's necessary. The participants will be also recomended dealing with the grasping and releasing activities in daily living at about 2-3 hours a day. In a way that every patient has to be the control of themselves, 1 week before kinesiotaping, immediately after kinesiotaping and 1 week after the period of kinesiotaping, patients will be evaluated with box and block test, nine hole peg test, modified house clasification and the active/passive wrist dorsiflexion range of motion
Study: NCT04060745

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cooling using a water-perfused vest
Description: BAT is activated by cold exposure. Each participant will have a shivering threshold test performed before entering the cooling arm. Participants will be gradually cooled (decreasing the temperature in the cooling vest by 0.6C every 15 min. until 3.8C) using a perfused cooling vest until they start to shiver. The temperature in which they start to shiver will be noted. If shivering has not occurred at 3.8C after 15 min. they will stay at the temperature for 45 min. in total or until shivering occurs. Shivering is defined by subjective perception of shivering by the participant in a numeric scale (NRS) where 0 refers to I'm not shivering and 10 refers to I'm shivering a lot and visual inspection by the investigator. The temperature used in the cooling arm will be set a few degrees above the shivering threshold test or at 3.8C if shivering did not occur.~During cooling indirect calorimetry and OGTT will be performed and finally the DMI scan will be performed

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thermoneutrality
Description: In the thermoneutrality arm participants will rest in thermoneutrality (22C) for one hour. Before the DMI scan indirect calorimetry will be performed
Study: NCT03126734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infant Massage course
Description: Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.~This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually.
Study: NCT01939275

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: copper Cu 64-DOTA-trastuzumab
Description: Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
Study: NCT04289298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Engage-A
Description: Therapist will encourage participants to engage in physical and social activities that are pleasurable or rewarding. Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training and utilizing Engage-A therapy
Description: Therapist will be trained in Engage-A therapy and given supervision while utilizing this therapy.
Study: NCT03979989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR capsule
Description: Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapentadol IR capsule
Description: Tapentadol IR capsule containing 93 mg tapentadol hydrochloride.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole capsule
Description: Omeprazole capsule containing 40 mg omeprazole.
Study: NCT03832452

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat (Treatment A)
Description: 2000 and 4000 mg; hard capsules for oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard capsules for oral administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: hard capsules for oral administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg; film-coated tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat (Treatment B)
Description: 1000 mg; hard capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucerastat (Treatment C)
Description: 4000 mg; hard capsules for oral administration
Study: NCT01797185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1104 modified dose regimen I
Description: Subjects who exited study CLR_09_21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1104 modified dose regimen II
Description: Subjects who received prior treatment regimen I

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPARC1104 modified dose regimen III
Description: Subjects who received no prior treatment regimen
Study: NCT03302663

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Addition of advanced imaging sequences for fetal MRI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Addition of advanced imaging sequences for fetal MRI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Addition of advanced imaging sequences for fetal MRI

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MRI scan
Description: Addition of advanced imaging sequences for fetal MRI
Study: NCT01684605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP 60μg
Description: Administrated NESP 60μg once intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-11101 60μg
Description: Administrated CKD-11101 60μg once intravenously
Study: NCT00676039

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gen-Citalopram
Description: Gen-Citalopram 40 mg (Genpharm, Generic)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Effexor XR
Description: Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
Study: NCT04981054

Intervention type: PROCEDURE
Intervention: Cystocele repair
Description: Repair of endopelvic fascia and anterior colporrhaphy